anti-PD-1 antibody and chemotherapy

DRUG2 trials

Sponsors

Fudan University

Conditions

HER2 Negative Breast CancerTriple-negative Breast Cancer

Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

RecruitingNCT05076682

Fudan UniversityTriple-negative Breast Cancer

Start: 2022-06-30End: 2027-03-31Target: 80Updated: 2025-12-03

Reverse HER2-negative Immune Resistant Breast Cancer

RecruitingNCT06731140

Fudan UniversityHER2 Negative Breast Cancer

Start: 2025-02-12End: 2027-10-31Target: 10Updated: 2025-11-17

Related Papers

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.

2025-06-25

Abstract PO1-14-07: Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial)

Cancer Research2024-05-02